The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options

The ubiquitin proteasome system (UPS) is the main cellular degradation machinery designed for controlling turnover of critical proteins involved in cancer pathogenesis, including hematological malignancies. UPS plays a functional role in regulating turnover of key proteins involved in cell cycle arr...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 12; no. 7; p. 1898
Main Authors Di Costanzo, Antonella, Del Gaudio, Nunzio, Conte, Lidio, Altucci, Lucia
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 14.07.2020
MDPI
Subjects
Apoptosis
Burkitt's lymphoma
Cancer
Cell cycle
Cell differentiation
Cell division
Deoxyribonucleic acid
DNA
DNA damage
DNA repair
Endoplasmic reticulum
Enzymes
Hematology
Kinases
Leukemia
Lymphoma
Medical prognosis
Multiple myeloma
Proteasomes
Proteins
R&D
Research & development
Review
Therapeutic applications
Ubiquitin
Online AccessGet full text

Cover

More Information
Summary:The ubiquitin proteasome system (UPS) is the main cellular degradation machinery designed for controlling turnover of critical proteins involved in cancer pathogenesis, including hematological malignancies. UPS plays a functional role in regulating turnover of key proteins involved in cell cycle arrest, apoptosis and terminal differentiation. When deregulated, it leads to several disorders, including cancer. Several studies indicate that, in some subtypes of human hematological neoplasms such as multiple myeloma and Burkitt’s lymphoma, abnormalities in the UPS made it an attractive therapeutic target due to pro-cancer activity. In this review, we discuss the aberrant role of UPS evaluating its impact in hematological malignancies. Finally, we also review the most promising therapeutic approaches to target UPS as powerful strategies to improve treatment of blood cancers.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors contributed equally to this work.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12071898